ClinicalTrials.gg
RecruitingNCT05315167Updated Dec 17, 2024

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

A Phase 1/2 interventional study of PRJ1-3024 in Advanced Solid Tumor and Advanced Solid Malignancies, sponsored by Zhuhai Yufan Biotechnologies Co., Ltd. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Zhuhai Yufan Biotechnologies Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
267
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in subjects with relapsed/refractory solid tumors. The study consists of two parts, one is a 3+3 dose escalation study and another is a pharmaceutical extension of RP2D.

Read the detailed description

Using dose escalation, the study will evaluate the safety, tolerability, PK, and pharmacodynamics of PRJ1-3024 and will determine the maximum tolerated dose in subjects with advanced solid tumors.

Participants with advanced solid tumor will receive PRJ1-3024 daily as an oral therapy and test the impact of of PRJ1-3024 on tumors.

This study will find the safe and tolerable recommended dose in subjects with advanced solid tumors in a open-label, 3+3 dose escalation study and use the RP2D to assess the preliminary efficacy of PRJ1-3024 in a long-term extension study.

02

Conditions studied

  • Advanced Solid Tumor
  • Advanced Solid Malignancies

Keywords

  • Maximum tolerated dose
  • Recommended Phase 2 dose
  • Dose Escalation
  • Hematopoietic progenitor kinase 1
  • PRJ1-3024
03

In context

Lead sponsor

Zhuhai Yufan Biotechnologies Co., Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Key Inclusion Criteria:
  • or cytologically confirmed locally advanced (unresectable) or r/r solid tumors for which no standard therapy is available or for whom standard therapy is considered unsuitable or intolerable.
  • Male or non-pregnant, non-lactating female subjects age ≥18 years.
  • Performance Status 0\~1.
  • Has at least 1 as defined by 1.1 criteria .
  • of >3 months, in the opinion of the Investigator.
  • Able to take oral medications and willing to record daily adherence to product.
  • Adequate hematologic parameters unless clearly due to the disease under study.
  • Adequate renal and hepatic function
  • Able to understand and willing to sign a written form.

Key Exclusion Criteria:

  • History of another
  • Known symptomatic requiring >10 mg/day of prednisolone.
  • Significant cardiovascular disease.
  • Known active , , AIDS-related illness.
  • Has received a within 30 days.
  • History of active disorders, or ongoing therapy or ongoing .
  • Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to \< Grade 2.
  • Receiving concurrent anti-cancer therapy, investigational product, strong inhibitors or inducers of cytochrome P450 3A () .
  • Prior treatment with hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
267 participants (estimated)

Study arms

  • Experimental
    Monotherapy Escalation

    3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level. PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.

    Drug: PRJ1-3024

  • Experimental
    Monotherapy Exploration of the recommended dose

    Upon completing Phase 1 and depending on data obtained, dose expansion may proceed in Phase 2 with several cohorts enrolled to confirm the tolerability of the RP2D of PRJ1-3024 (determined in Phase 1). PRJ1-3024 is administered orally once daily. The starting dose is determined by clinical effecacy data from Phase 1, and treatment may continue for up to 2 years as long as the subject experiences clinical benefit in the opinion of the Investigator and shows no signs or symptoms of unequivocal progression of disease.

    Drug: PRJ1-3024

Interventions

  • PRJ1-3024 is provided as capsules and is administered orally once a day.

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity (DLT) events during the DLT monitoring period

    Safety listings and pharmacokinetic listings will be used for evaluation

    Time frame: Day 1 to Day 21

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Characterized by type, seriousness, relationship to study treatment, timing, and severity.

    Time frame: 24 months

  2. Pharmacokinetic parameter# Accumulation ratio

    to estimate the accumulation of PRJ1-3024 from time 0 to the time of last quantifiable concentration after multiple administration

    Time frame: 24 months

  3. Objective response rate (ORR)

    estimated by the proportion of subjects having a complete response (CR) or partial response (PR) with use of RECIST v1.1 criteria.

    Time frame: 24 months

  4. Duration of response (DOR)

    defined as time from the first occurrence of a documented objective response to the time of relapse or death from any cause.

    Time frame: 24 months

  5. Pharmacokinetic parameter#AUC0-last#

    Area under the concentration-time curve AUC from time 0 to the time of the last quantifiable concentration

    Time frame: 24 months

  6. Pharmacokinetic parameter#Maximum observed concentration (Cmax)

    assessed as time from time 0 to the time of the last quantifiable concentration

    Time frame: 24 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for May 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2022
First posted
Apr 7, 2022
StartActual
May 30, 2022
Primary completionEst.
May 15, 2027
CompletionEst.
Nov 15, 2027
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05315167
Lead sponsor
Zhuhai Yufan Biotechnologies Co., Ltd
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
May 30, 2022
Primary completion
May 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Dec 17, 2024

Study contacts

Liting Lai
Contact
vivi.lai@ming-med.com
8617728075858
Hui ouyang, Dr.
study director · VP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hpk1 Inhibitor PRJ1-3024

Start the discussion